Federal funding enabled research on THCV, CBD and diabetes type 2
NCBI (National Center for Biotechnology) and NIH (National Institute of Health) conducted a federally funded randomized, double-blind, placebo-controlled, parallel group pilot study concerning CBD and diabetes type 2. They reviewed interactions between CBD and THCV and glycemic and lipid activity in those diagnosed with type 2 diabetes. Scientists produced conclusive evidence that THC and CBD compounds are highly effective in treating multiple aspects of type 2 diabetes.
Compounds found in hemp reduce fasting glucose levels and improve function of natural insulin-producing organs. Furthermore, THCV and CBD stimulate the production of vital proteins that increase healthy levels of HDL cholesterol.
HDL cholesterol is a healthy cholesterol that naturally breaks down it’s not-so-healthy counterpart, LDL cholesterol. Additionally, it increases the potential for long-term cardiovascular health for those living with type 2 diabetes. (https://www.sharecare.com/health/cholesterol/what-is-cholesterol)
THCV & CBD and Diabetes Type 2
Until recently, most people were only familiar with THC (tetrahydrocannabinol). Understandably so, because it was (and to many, still is) the most widely known chemical compound in cannabis.
It’s the first one you may think of when you conjure images of marijuana plants and stoners having a chill time. Marijuana is now therapeutically legal in most states. Furthermore, there are a variety of states allowing recreational consumption. As such, the federal government is finally forming programs to enable legal research on CBD and diabetes type 2 and other conditions.
The federal government is finally offering the medical community an opportunity to legitimize claims that cannabis has therapeutic benefits. Additionally, hemp activists get the opportunity to demonstrate that there are way more compounds to hemp and marijuana than THC. Hemp is a non-psychoactive herb with supplemental cannabinoids.
Qualified hemp CBD product makers can extract CBD for consumers to take advantage of its healthful nature. Furthermore, a professional CBD extractor is able to use lower temperatures to neutralize psychoactive properties of THC. Cooks are able to extract CBD and other little known compounds like THCV at a stabilizing temperature.
CBD reacts to the endocannabinoid differently than THC, so it doesn’t require as much heat for activation. At the right temperature, a cook is able to maximize CBD potency while rendering THC effectively useless. Therefore, CBD and diabetes type 2 can finally get more attention.
What is THCV?
THCV is a compound in marijuana that has no psychoactive properties. Furthermore, it has at least three known health benefits that are highly relevant to both type 1 and type 2 diabetes. Medical professionals have learned that THCV is able to reduce blood sugar levels. In the most recent study conducted, scientists also discovered THCV was able to assist with pancreatic function. Patients with improved functionality of the pancreas consequently have a natural ability to produce healthy levels of insulin. Finally, this compound aids in healthy bone growth and assists with prevention of long-term symptoms of both type 1 and type 2 diabetes such as bone deterioration and weakening.
Objectives of Pilot Trial
The primary objective of the study was to raise HDL-cholesterol levels. Secondary objectives were to trigger changes in glycemic activity by minimizing and regulating glucose and liver triglyceride levels; control body weight; increase healthy production of lipids, proteins, and insulin; improve cardiovascular health; identify and treat markers of inflammation; and regulate adipose tissue distribution.
Treatment of Randomized Groups in the Study regarding CBD and diabetes type 2
The CBD and diabetes type 2 study included 62 test subjects diagnosed with noninsulin-treated, type 2 diabetes who were split into five groups. One group received 100 mg of CBD twice daily. The second group received 5mg of THCV twice daily. The third group received both 5 mg of CBD and 5 mg of THCV twice daily. The fourth group received 100 mg of CBD and 5 mg of THCV twice daily, and the fifth group received placebo drugs.
Breakdown of research on THCV & CBD and diabetes type 2
One of the most impressive results was the significant decrease in fasting plasma glucose. Prolonged fasting causes the pancreas to produce a hormone known as glucagon. Glucagon, then, causes the liver to release glucose. In an average person who does not have diabetes, the body would simply create enough insulin to regulate glucose levels. One of the primary symptoms of diabetes is irregular insulin production. This is coupled by a reduction of production when insulin is produced.
Patients in the study who were taking THCV experienced a decrease in fasting glucose levels of 1.2 mmol/L – a stark contrast to the placebo group in which the average decrease was less than 0.05 mmol/L. (https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685)
Pancreatic beta-cell function was increased dramatically with THCV treatments.
THCV also resulted in improved pancreatic β-cell function, improving by 44.51 points in comparison to the placebo group, which showed a difference of less than 0.01. This is a vital discovery for type 2 diabetes – a condition that results in failure of pancreatic β-cell function and resistance to insulin. With long-term treatment of THCV, it’s possible for the pancreatic β-cell function to remain at optimal levels in patients living with type 2 diabetes (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982570/)
THCV raised diponectin levels at a rate of -5.9 x 10(6) pg/ml over less than 0.01 pg/ml with the placebo group. Adiponectin is a protein hormone that works in the body to regulate glucose levels and break down fatty acids (https://en.wikipedia.org/wiki/Adiponectin)
Another protein that experienced significant production with THCV is apolipoprotein A – which is a protein that assists HDL cholesterol in removing bad LDL cholesterol from the body and assisting with healthy adipose tissue distribution. Patients who had received CBD had protein levels around -6.02 μmol/L – a significant difference from the placebo group who had levels of less than 0.01. (https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=apolipoprotein_a)
Patients who were taking CBDs experienced a significant decrease in resistin levels (-898 pg/ml, compared to less than 0.05 in the placebo group). While there was not a significant impact in the HDL plasma itself, resistin is linked to high levels of LDL cholesterol. Reducing the level of resistin helps to prevent the buildup of LDL in arteries and helps to minimize the risk of heart failure and other cardiovascular diseases. (https://www.news-medical.net/news/20121029/Resistin-protein-causes-high-levels-of-bad-cholesterol.aspx)
Conclusion on CBD and diabetes type 2
Test subjects tolerated both CBD and THCV well. Furthermore, scientists were able to confirm the benefits of THCV and CBD in the long-term health and management of type 2 diabetes during this 13 week pilot study.
Skeptics and believers alike are finally being shown conclusive results. As such, federal officials are more confident funding studies. Millions will benefit from more knowledge of CBD as a vital supplement.
Scientists can only learn more about CBD and diabetes type 2 and other conditions by conducting more research.